Ieq Capital LLC Grows Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Ieq Capital LLC boosted its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 21.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 62,034 shares of the company's stock after acquiring an additional 10,800 shares during the period. Ieq Capital LLC owned about 0.10% of Twist Bioscience worth $2,883,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Massachusetts Financial Services Co. MA increased its stake in Twist Bioscience by 215.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company's stock valued at $1,324,000 after purchasing an additional 20,035 shares during the last quarter. Barclays PLC lifted its holdings in shares of Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after purchasing an additional 104,420 shares during the last quarter. FMR LLC boosted its position in shares of Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company's stock valued at $9,875,000 after purchasing an additional 12,327 shares during the period. Avanza Fonder AB acquired a new position in Twist Bioscience during the fourth quarter worth approximately $1,059,000. Finally, BNP Paribas Financial Markets lifted its stake in Twist Bioscience by 128.1% in the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company's stock valued at $1,718,000 after buying an additional 21,357 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages have recently commented on TWST. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the company an "overweight" rating in a report on Monday, February 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. Wolfe Research initiated coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 target price for the company. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Robert W. Baird lifted their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $54.40.

Remove Ads

Twist Bioscience Price Performance

NASDAQ TWST traded up $0.52 during mid-day trading on Wednesday, hitting $41.33. The stock had a trading volume of 711,402 shares, compared to its average volume of 878,495. The company has a 50 day simple moving average of $47.80 and a 200 day simple moving average of $45.70. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -12.23 and a beta of 1.87. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business's revenue for the quarter was up 24.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.75) EPS. Equities analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 5,886 shares of the business's stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the transaction, the chief financial officer now owns 110,096 shares in the company, valued at $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 2,216 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $116,783.20. Following the completion of the sale, the chief executive officer now owns 674,718 shares of the company's stock, valued at approximately $35,557,638.60. This trade represents a 0.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,180 shares of company stock valued at $1,821,971 in the last ninety days. Corporate insiders own 3.01% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.